MASH临床试验中组织学分级与分期系统标准化应用的共识声明
国际MASLD病理学组(IMPG)由25名肝脏病理专家和1名统计学家组成,通过Delphi共识流程制定MASH临床试验肝活检组织学评估指南。工作组合计提出278条初始声明,经两轮Delphi后最终形成192条共识度≥80%的声明,涵盖活检处理、MASH诊断及分级分期标准。
要点
- IMPG发布192条共识声明,标准化MASH临床试验肝活检的组织学评估与评分。
- 共识旨在减少观察者间变异,提升分级分期精确性及MASL/MASH亚型诊断一致性。
- 声明可为开发监督式机器学习定量组织学算法提供依据。
核心结论
- IMPG首次提供指南以促进肝脏病理学家在MASH临床试验肝活检组织病理学评估与评分上达成共识,并可指导MASLD定量组织学监督式机器学习算法的开发。
研究设计与样本
- 国际MASLD病理学组(IMPG)由25名专家肝脏病理学家和1名统计学家组成,设立三个工作亚组生成声明,并通过Delphi共识程序评估。
主要发现
- IMPG工作组共发布278条初始声明,第一轮Delphi评估后162条声明达成≥80%同意。
- 其余116条声明经讨论后修订或不再考虑,产生的33条修订声明进入第二轮Delphi评估。
- 最终192条声明达成≥80%同意。
关键数值与推荐
- 最终共识声明共192条,均达成≥80%同意。
- 初始声明278条,第一轮后162条达成≥80%同意,33条修订声明进入第二轮。
临床怎么用
- 声明可用于标准化MASH临床试验中肝活检的组织学判读与评分,减少观察者间与观察者内变异。
- 声明可为开发基于人工智能的MASH临床试验分级分期算法提供基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Assessment of histologic disease activity (grading) and fibrosis (staging) is a prerequisite for patient selection and evaluation of treatment response in clinical trials of metabolic dysfunction-associated steatohepatitis (MASH). The lack of universally accepted definitions of histological components required for metabolic dysfunction-associated steatotic liver disease (MASLD) grading and staging, inconsistent histologic interpretations, and the absence of guidelines on how to apply currently used scoring systems, contribute to high interobserver variation and influence supervised machine learning algorithms. METHODS: The International MASLD Pathology Group (IMPG), comprising 25 expert liver pathologists and one statistician, was established to develop guidance for the histological assessment of liver biopsies in MASH clinical trials and to define standards for liver biopsy processing, as well as to refine criteria for histological MASLD grading and staging. Statements were generated by three IMPG working subgroups and evaluated through a Delphi consensus procedure. RESULTS: The IMPG working groups issued a total of 278 primary statements, which were evaluated in the first Delphi round, yielding 162 statements with 80% or higher agreement. The remaining 116 statements were discussed and either revised or not further considered. The resulting 33 revised statements were evaluated in a second Delphi round, yielding 192 final statements with 80% or higher agreement. CONCLUSION: For the first time, the IMPG statements provide guidelines to promote consensus among liver pathologists on the histopathological evaluation and scoring of liver biopsies for MASH clinical trials. Furthermore, they may inform the development of supervised machine learning algorithms for quantitative histology assessments of MASLD. IMPACT AND IMPLICATIONS: Inter- (and intra-) observer variations in the histological interpretation of key morphological features of metabolic dysfunction-associated steatohepatitis (MASH) limit the precision of histological grading and staging, as well as the diagnosis of the histological subtypes, MASL and MASH. This is thought to account, at least in part, for screening failure and variable placebo response rates in clinical trials, potentially obscuring treatment effects. The International MASLD Pathology Group, consisting of 25 expert liver pathologists, generated consensus statements for histopathological procedures, technical aspects and histological criteria for the diagnosis of MASH, as well as for grading disease activity and staging fibrosis. These may provide a basis for standardized histologic interpretation and the development of AI-based grading and staging algorithms for clinical trials of MASH.
引用
- Lackner C, Gouw ASH, Avancini Ferreira Alves V, et al. Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials. J Hepatol. 2025. PMID: 41072805. doi:10.1016/j.jhep.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。